CompaniesBiotech and healthUpdated Oct 6, 2026
Consano Bio
Private. Consano Bio is a clinical-stage biotechnology company advancing a novel therapeutic designed to address serious pain conditions where conventional therapies are limited or ineffective.
- Last round
- $15M Financing
- Backed by
- Not recorded
- Launched
- 2023
- People
- 4
Overview
Updated Oct 6, 2026
Every fact carries a numbered source. Where we can't source something, it says so.
Identity fields from the company record are sourced where a source is recorded; those have no number.
Funding
How much has Consano Bio raised?
Rounds and backers, each sourced.
Rounds
- 2026-10-05
Financing · $15M raised3
Led by Not recorded
Backers
No backer recorded. Backers are the lead investors a sourced round names.
Opportunities For accredited investors
Ways to invest in this company through an Alphaneo vehicle, when one exists. This section looks the same on every company page until you have an accredited profile.
Opportunities, terms and data rooms are shown to accredited investors. Creating a profile takes two minutes, and you’re notified first when anything opens.
No live opportunities right now. Accredited investors are notified first when one opens.
Create an accredited profileA vehicle is never smaller than $1,000,000.
People
Who leads Consano Bio?
Names and titles only, each sourced.
Sources
Every claim on this page traces to one of these. The numbers match the citations above.
- 1Consano Bio | About Us opens in a new tabFounded, People · accessed Oct 6, 2026
- 2Consano Bio | Transforming the Standard of Care in Painful & Debilitating Orthopedic Conditions opens in a new tabHeadquarters, Sector, Website · accessed Oct 6, 2026
- 3Consano Bio Raises More Than $15 Million in Oversubscribed Financing to Advance C-1101 in Chronic Painful Lumbosacral Radiculopathy (Chronic Sciatica) opens in a new tabTotal raised, Funding · accessed Oct 6, 2026